A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in ...

Without a specific news headline driving the move, DexCom (DXCM) sits at a recent close of US$70.69, leaving investors weighing its continuous glucose monitoring business against recent share price ...

Shares of DexCom Inc. DXCM shed 1.38% to $67.79 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.21% to 6,781.48 and Dow ...

They are down, but they are not out.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

(Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025.

Out of the diabetes patients surveyed, 46% said they would feel more in control of their disease in everyday life if they ...

It will be a final decider with Marist College of Athlone next week.

The Helsinki‑based company offers AI-enabled biometric and gesture recognition technology that allows for device control with natural movements.

MiniMed (MMED) shares drop 4.8% in Nasdaq debut, opening at $19.05 after raising $560M in IPO. Medtronic (MDT) retains 90% stake in diabetes device spinoff.

In other news, Australia’s IP office has announced expanded search options, and an EPO report shed light on slow progress ...

In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...